The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia

Nature Communications

Volumn 7, Issue , 2016, Pages

  Ashton, Thomas M ^a   Fokas, Emmanouil ^a   Kunz Schughart, Leoni A ^a,b   Folkes, Lisa K ^a   Anbalagan, Selvakumar ^a   Huether, Melanie ^b   Kelly, Catherine J ^a   Pirovano, Giacomo ^a   Buffa, Francesca M ^a   Hammond, Ester M ^a   Stratford, Michael ^a   Muschel, Ruth J ^a   Higgins, Geoff S ^a   McKenna, William Gillies ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Dresden Rossendorf   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; AMSACRINE; ANTIMYCIN A1; ATOVAQUONE; BERBERINE; CYCLOSPORIN; CYTARABINE; DOCETAXEL; EMETINE; FENOFIBRATE; FLUOROURACIL; HYDROXYPROGESTERONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; ITRACONAZOLE; METFORMIN; MITHRAMYCIN; MITOMYCIN; NICLOSAMIDE; NIMORAZOLE; PENTAMIDINE; PHENFORMIN; PYRIMIDINE; PYRVINIUM EMBONATE; SORAFENIB; SULOCTIDIL; UBIQUINOL CYTOCHROME C REDUCTASE; ANTIMALARIAL AGENT; BIGUANIDE DERIVATIVE; HIF1A PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

BIOTECHNOLOGY; CANCER; CELLS AND CELL COMPONENTS; CHEMICAL COMPOUND; DRUG DEVELOPMENT; HYPOXIA; OXYGEN CONSUMPTION; SENSITIVITY ANALYSIS; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FADU CELL LINE; H1299 CELL LINE; HCT116 CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PYRIMIDINE SYNTHESIS; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; SINGLE DRUG DOSE; TUMOR HYPOXIA; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECT; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; OXYGEN CONSUMPTION; PATHOLOGY; RADIATION TOLERANCE; TUMOR CELL CULTURE;

MUS MUSCULUS;

ANIMALS; ANTIMALARIALS; ATOVAQUONE; BIGUANIDES; ELECTRON TRANSPORT COMPLEX III; HIGH-THROUGHPUT SCREENING ASSAYS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE, INBRED BALB C; MICE, NUDE; OXYGEN CONSUMPTION; PYRIMIDINES; RADIATION TOLERANCE; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR HYPOXIA;

EID: 84979642376     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12308     Document Type: Article

References (48)

1. Dhani, N., Fyles, A., Hedley, D. & Milosevic, M. The clinical significance of hypoxia in human cancers. Semin. Nucl. Med. 45, 110-121 (2015).
2. Okunieff, P. et al. Angiogenesis determines blood flow, metabolism, growth rate, and ATPase kinetics of tumors growing in an irradiated bed: 31P and 2H nuclear magnetic resonance studies. Cancer Res. 51, 3289-3295 (1991).
3. Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410 (2011).
4. Overgaard, J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother. Oncol. 100, 22-32 (2011).
5. Fokas, E. et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 72, 239-248 (2012).
6. Grimes, D. R., Kelly, C., Bloch, K. & Partridge, M. A method for estimating the oxygen consumption rate in multicellular tumour spheroids. J. R. Soc. Interface 11, 20131124 (2014).
7. Kelly, C. J. et al. Regulation of O consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother. Oncol. 111, 72-80 (2014).
8. Secomb, T. W., Hsu, R., Ong, E. T., Gross, J. F. & Dewhirst, M. W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. (Madr). 34, 313-316 (1995).
9. Ellinghaus, P. et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2, 611-624 (2013).
10. Lin, X. et al. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc. Natl Acad. Sci. USA 105, 174-179 (2008).
11. Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).
12. Zannella, V. E. et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res. 19, 6741-6750 (2013).
13. Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254, 2669-2676 (1979).
14. Lee, K. et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. USA 106, 17910-17915 (2009).
15. Khaw, M. & Panosian, C. B. Human antiprotozoal therapy: past, present, and future. Clin. Microbiol. Rev. 8, 427-439 (1995).
16. Harada, Y., Ishii, I., Hatake, K. & Kasahara, T. Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 319, 83-88 (2012).
17. Veal, G. J. et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin. Cancer Res. 11, 5893-5899 (2005).
18. Nixon, G. L. et al. Antimalarial pharmacology and therapeutics of atovaquone. J. Antimicrob. Chemother. 68, 977-985 (2013).
19. Birth, D., Kao, W. C. & Hunte, C. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat. Commun. 5, 4029 (2014).
20. Biagini, G. A. et al. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol. Pharmacol. 73, 1347-1355 (2008).
21. Nilsen, A. et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci. Transl. Med. 5, 177-137 (2013).
22. Knecht, W., Henseling, J. & Loffler, M. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem. Biol. Interact. 124, 61-76 (2000).
23. Hail, Jr N., Chen, P. & Bushman, L. R. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia 12, 464-475 (2010).
24. Loffler, M., Jockel, J., Schuster, G. & Becker, C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol. Cell. Biochem. 174, 125-129 (1997).
25. Elford, H. L. Effect of hydroxyurea on ribonucleotide reductase. Biochem. Biophys. Res. Commun. 33, 129-135 (1968).
26. Pasternak, C. A. & Handschumacher, R. E. The biochemical activity of 6-azauridine: interference with pyrimidine metabolism in transplantable mouse tumors. J. Biol. Chem. 234, 2992-2997 (1959).
27. Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol. 46, 135-146 (1998).
28. Overgaard, J. et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362, 933-940 (2003).
29. Sugie, C. et al. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J. Radiat. Res. 46, 453-459 (2005).
30. Hassan Metwally, M. A., Jansen, J. A. & Overgaard, J. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial. Clin. Oncol. (R. Coll. Radiol). 27, 168-175 (2015).
31. Overgaard, J., Overgaard, M. & Timothy, A. R. Studies of the pharmacokinetic properties of nimorazole. Br. J. Cancer 48, 27-34 (1983).
32. Dixon, R., Pozniak, A. L., Watt, H. M., Rolan, P. & Posner, J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob. Agents Chemother. 40, 556-560 (1996).
33. Falloon, J. et al. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy 19, 1050-1056 (1999).
34. Rolan, P. E., Mercer, A. J., Tate, E., Benjamin, I. & Posner, J. Disposition of atovaquone in humans. Antimicrob. Agents Chemother. 41, 1319-1321 (1997).
35. Beuneu, C. et al. Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide. Free Radic. Biol. Med. 28, 1206-1213 (2000).
36. Khutornenko, A. A. et al. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc. Natl Acad. Sci. USA 107, 12828-12833 (2010).
37. Chandel, N. S. et al. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 23, 569-570 (2016).
38. Dowling, R. J. et al. Metformin pharmacokinetics in mouse tumors: implications for human therapy. Cell Metab. 23, 567-568 (2016).
39. Graham, G. G. et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81-98 (2011).
40. Kimura, H. et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56, 5522-5528 (1996).
41. Koritzinsky, M. & Wouters, B. G. The roles of reactive oxygen species and autophagy in mediating the tolerance of tumor cells to cycling hypoxia. Semin. Radiat. Oncol. 23, 252-261 (2013).
42. Miao, Z. F. et al. Influence of different hypoxia models on metastatic potential of SGC-7901 gastric cancer cells. Tumour Biol. 35, 6801-6808 (2014).
43. Okajima, M. et al. Anoxia/reoxygenation induces epithelial-mesenchymal transition in human colon cancer cell lines. Oncol. Rep. 29, 2311-2317 (2013).
44. Salabei, J. K., Gibb, A. A. & Hill, B. G. Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat. Protoc. 9, 421-438 (2014).
45. Gurule, S., Goswami, D., Khuroo, A. H. & Monif, T. LC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma. Biomed. Chromatogr. 24, 497-505 (2010).
46. Porta, V. et al. HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies. J. Pharm. Biomed. Anal. 46, 143-147 (2008).
47. Chaiyarit, S. & Thongboonkerd, V. Comparative analyses of cell disruption methods for mitochondrial isolation in high-throughput proteomics study. Anal. Biochem. 394, 249-258 (2009).
48. Moss, J. et al. Break-induced ATR and Ddb1-Cul4(Cdt)(2) ubiquitin ligase-dependent nucleotide synthesis promotes homologous recombination repair in fission yeast. Genes Dev. 24, 2705-2716 (2010).